A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients With Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (BMT CTN 1501)
收藏DataCite Commons2026-02-05 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008644/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The study is a Phase II randomized, open label, multicenter trial designed to identify
whether sirolimus is a potential alternative to prednisone as an up-front treatment for
patients with standard-risk acute GVHD defined according to clinical and biomarker-based risk
stratification. This trial incorporates both a novel up front GVHD therapy (sirolimus) as
well as a novel BMT CTN developed acute GVHD biomarker test.
提供机构：
Vivli
创建时间：
2022-12-07
